Market Report Source

Overview

Introduction

Alexion Pharmaceuticals (Alexion) is a biotechnology company engaged in the discovery and development of therapeutic products for the treatment of hematological diseases, cancer, and autoimmune disorders. The company started marketing Soliris in the US in March 2007 for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis.

Scope

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies

Highlights

Alexion has one marketed product, Soliris, approved for paroxysmal nocturnal hemoglobinuria (PNH), a rare, disabling and life-threatening blood disorder defined by chronic red blood cell destruction, or hemolysis. It also has preclinical programs in asthma, macular degeneration, B-Chronic lymphocytic leukemia and multiple myeloma. Alexion derives revenues from research and development support payments, license fees and milestone payments under collaborations with third parties such as P&G, and amounts received from various government grants. During the period 2002-2006, the company’s total revenues decreased at a CAGR of 30%, from $7 million to $2 million. Alexion’s major contributor to sales growth out to 2010 will be the product sales of Soliris which was launched in the year 2007. Revenues from this stream are expected to contribute the absolute sales growth of +$370 million during the period 2006-2010.

Reasons to Purchase

Access all the important information and analysis on the company in a single report Understand company’s strengths, weaknesses, opportunities and threats along with business strategy and value chain Gain access to company’s adjusted five year financial data along with key ratios and market capitalization.

Table of Contents

Overview
Catalyst
Summary
Company Structure
Company Overview and Key Facts
Business Description
History
Locations and Subsidiaries
Company Financials
Stock Market Performance
P&L
Balance Sheet
Cash Flow
Business Segment Performance
Products & Services
Marketed Products
Pipeline Products
AC Forecast Product Sales
Competitors and Strategic Business Relationships
Top Competitors
Key Suppliers
Key Clients
Shareholding Structure
Strategy
Company View
Strategy
SWOT Analysis
Overview
Strengths
Weaknesses
Opportunities
Threats
Value Chain Analysis
Overview
Discovery and Product Development
Manufacturing
Sales
Scorecard
Overview
Scorecard Analysis
Key Employees
List of Key Employees
Key Employee Biographies
Financial and Operational Overview
Financial and Operational Overview
Appendix
Ask the analyst
Datamonitor consulting
Disclaimer

FIGURES
Figure 1: Alexion Pharmaceuticals – Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)
Figure 2: Alexion Pharmaceuticals – Key Strategic Revenues, 2006-2010 ($ Mn)

TABLES
Table 1: Alexion Pharmaceuticals – Key Facts
Table 2: Alexion Pharmaceuticals – Other Locations and Subsidiaries
Table 3: Alexion Pharmaceuticals – Year-End Share Price and Market Capitalization, 2002-2006 ($)
Table 4: Alexion Pharmaceuticals – Key Events Impacting Share Price Performance
Table 5: Alexion Pharmaceuticals – Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)
Table 6: Alexion Pharmaceuticals – Operating Cost Ratio Analysis, 2002-2006 (% of total revenues)
Table 7: Alexion Pharmaceuticals – Balance Sheet, 2002-2006 ($ Mn)
Table 8: Alexion Pharmaceuticals – Cash Flow, 2002-2006 ($ Mn)
Table 9: Alexion Pharmaceuticals – Revenue Breakdown, 2002-2006 ($ Mn)
Table 10: The Medicines Company – Marketed Products
Table 11: Alexion Pharmaceuticals – In-house Pipeline Products
Table 12: Alexion Pharmaceuticals – Forecast Sales, 2006-2010 ($ Mn)
Table 13: Alexion Pharmaceuticals – Top Competitors
Table 14: Alexion Pharmaceuticals – Key Suppliers
Table 15: Alexion Pharmaceuticals – Key Shareholders
Table 16: Alexion Pharmaceuticals – SWOT Analysis Summary
Table 17: Alexion Pharmaceuticals – Value Chain Analysis
Table 18: Alexion Pharmaceuticals – Scorecard
Table 19: Alexion Pharmaceuticals – Key Employees
Table 20: Alexion Pharmaceuticals – Financial and Operational Overview